Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-21-010287
Filing Date
2021-02-12
Accepted
2021-02-12 17:32:05
Documents
2
Period of Report
2021-02-10

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 2207
2 POA DOCUMENT poa.txt EX-24.3_962681 3365
  Complete submission text file 0001209191-21-010287.txt   7041
Mailing Address C/O IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E., SUITE 310 SEATTLE WA 98102
Business Address
Yurasov Sergey (Reporting) CIK: 0001686295 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39351 | Film No.: 21630041

Mailing Address 357 TEHAMA STREET, FLOOR 3 SAN FRANCISCO CA 94103
Business Address 357 TEHAMA STREET, FLOOR 3 SAN FRANCISCO CA 94103 (415) 754-3517
Nuvation Bio Inc. (Issuer) CIK: 0001811063 (see all company filings)

EIN.: 850862255 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations